BLPH - ベレロフォン・セラピュ―ティクス (Bellerophon Therapeutics Inc.) ベレロフォン・セラピュ―ティクス

 BLPHのチャート


 BLPHの企業情報

symbol BLPH
会社名 Bellerophon Therapeutics Inc (ベレロフォン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Bellerophon Therapeutics Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system INOpulse with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs which minimizes the amount of drug required for treatment. The Company''s second program BCM is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI) which is a type of severe heart attack. The Company''s BCM is in PRESERVATION I clinical trial.   ベレロフォン・セラピュ―ティクスは、米国のバイオ医薬品会社。心肺や心臓疾患の治療における医療ニ―ズに対応する薬と装置を中心に製品開発を行う。最初のプログラムであるINOpulseは、拍動一酸化窒素送達デバイスに基づいて開発され、肺動脈高血圧症の治療のための製品と、慢性閉塞性肺疾患に関連する肺高血圧症の治療用の製品を提供する。   
本社所在地 184 Liberty Corner Road Suite 302 Warren NJ 07059 USA
代表者氏名 Jonathan M. Peacock ジョナサン・M・ピーコック
代表者役職名 Chairman of the Board President 取締役会長会長
電話番号 +1 908-574-4770
設立年月日 41548
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 20人
url www.bellerophon.com
nasdaq_url https://www.nasdaq.com/symbol/blph
adr_tso
EBITDA EBITDA(百万ドル) -29.49600
終値(lastsale) 1.23
時価総額(marketcap) 71092323.51
時価総額 時価総額(百万ドル) 67.62441
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 41.72541
当期純利益 当期純利益(百万ドル) -39.12000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Bellerophon Therapeutics Inc revenues was not reported. Net loss decreased 68% to $7.4M. Lower net loss reflects Change in fair value of common stock war increase from $12M (expense) to $3.4M (income) Interest and other income increase from $53K to $190K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.72 to -$0.13.

 BLPHのテクニカル分析


 BLPHのニュース

   Mid-Afternoon Market Update: Dow Surges 250 Points; Bellerophon Therapeutics Shares Slide - Stocks News Feed  2020/11/23 19:35:46 Stocks News Feed
Toward the end of trading Monday, the Dow traded up 0.89% to 29,522.86 while the NASDAQ rose 0.08% to 11,864.80. The S&P also rose, gaining 0.37% to 3,570.63. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 12,249,520 cases with around 256,790 deaths. India confirmed a… Read More »Mid-Afternoon Market Update: Dow Surges 250 Points; Bellerophon Therapeutics Shares Slide
   Mid-Afternoon Market Update: Dow Surges 250 Points; Bellerophon Therapeutics Shares Slide  2020/11/23 14:35:00 Benzinga
Toward the end of trading Monday, the Dow traded up 0.89% to 29,522.86 while the NASDAQ rose 0.08% to 11,864.80. The S&P also rose, gaining 0.37% to …
   The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings  2020/11/01 14:40:39 Benzinga
Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns. Several big-name pharma companies, including Merck & Co. Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ), reported earnings during the week. The earnings news flow was broadly mixed. Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) was among the biggest decliners, as it halted a late-stage trial of its Duchenne muscular dystrophy drug. On the other hand, Scholar Rock Holding Corp. (NASDAQ: SRRK ) was up about over 175% during the week, reacting to positive mid-stage results for spinal muscular atrophy drug. On the COVID-19 front, Regeneron Pharmaceuticals Inc. said it is (NASDAQ: REGN ) halting the Phase 3 trial of its antibody cocktail in patients with severe COVID-19, citing safety issue. Kala Pharmaceuticals Inc. (NASDAQ: KALA ) announced FDA approval for its dry eye disease drug, while Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ) communicated a delay in the decision for its treatment option for chemotherapy-induced neutropenia, as the FDA could not inspect a plant in South Korea due to COVID-19.
   Bellerophon Therapeutics (NASDAQ:BLPH) Cut to Sell at Zacks Investment Research  2020/10/24 08:18:45 Transcript Daily
Zacks Investment Research lowered shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a hold rating to a sell rating in a report published on Wednesday, Zacks.com reports. According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of […]
   Zacks Investment Research Downgrades Bellerophon Therapeutics (NASDAQ:BLPH) to Sell  2020/10/23 05:32:52 Zolmax News
Bellerophon Therapeutics (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product […]
   Bellerophon Therapeutics (NASDAQ:BLPH) Cut to Sell at Zacks Investment Research  2020/10/24 08:18:45 Transcript Daily
Zacks Investment Research lowered shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a hold rating to a sell rating in a report published on Wednesday, Zacks.com reports. According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of […]
   Zacks Investment Research Downgrades Bellerophon Therapeutics (NASDAQ:BLPH) to Sell  2020/10/23 05:32:52 Zolmax News
Bellerophon Therapeutics (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product […]
   Bellerophon Therapeutics (NASDAQ:BLPH) Stock Rating Lowered by Zacks Investment Research  2020/10/21 19:36:42 The Olympia Report
Bellerophon Therapeutics (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The […]
   Bellerophon to Present at Two September Investor Conferences  2020/09/14 12:30:00 GlobeNewswire
WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage…
   Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19  2020/07/13 12:30:00 GlobeNewswire
Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States
   Bellerophon to Present at Two September Investor Conferences  2020/09/14 12:30:00 GlobeNewswire
WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage…
   Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19  2020/07/13 12:30:00 GlobeNewswire
Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States
   Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes  2020/06/29 12:00:00 GlobeNewswire
WARREN, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on…
   Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19  2020/03/31 12:30:00 GlobeNewswire
WARREN, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on…
   Stock Alert: Bellerophon Therapeutics (BLPH) Breathes Easy  2020/03/30 08:48:00 RTT News
The University Of Miami School Of Medicine has for the first time initiated treatment of a COVID-19 patient with Bellerophon Therapeutics Inc.'s (BLPH) INOpulse inhaled nitric oxide system under the emergency expanded access program.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ベレロフォン・セラピュ―ティクス BLPH Bellerophon Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)